Edwards Lifesciences Corp
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income
| Years Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net income | $4,169.7 | $1,399.4 | $1,521.9 |
| Other comprehensive (loss) income, net of tax (Note 17): | |||
| Foreign currency translation adjustments | (59.6) | 4.3 | (46.3) |
| Unrealized gain (loss) on hedges | 37.0 | (23.1) | (5.9) |
| Unrealized pension credits (costs) | 0.1 | (9.9) | 13.7 |
| Unrealized gain (loss) on available-for-sale investments | 20.8 | 40.8 | (58.7) |
| Other comprehensive (loss) income, net of tax | (1.7) | 12.1 | (97.2) |
| Comprehensive income | 4,168.0 | 1,411.5 | 1,424.7 |
| Comprehensive loss attributable to noncontrolling interest | (4.9) | (3.0) | — |
| Comprehensive income attributable to Edwards Lifesciences Corporation | $4,172.9 | $1,414.5 | $1,424.7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.